Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 167

1.

Radiation Promptly Alters Cancer Live Cell Metabolic Fluxes: An In Vitro Demonstration.

Campos D, Peeters W, Nickel K, Burkel B, Bussink J, Kimple R, van der Kogel A, Eliceiri KW, Kissick MW.

Radiat Res. 2016 Apr 29. [Epub ahead of print]

PMID:
27128739
2.

Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology.

Wu W, Parmar C, Grossmann P, Quackenbush J, Lambin P, Bussink J, Mak R, Aerts HJ.

Front Oncol. 2016 Mar 30;6:71. doi: 10.3389/fonc.2016.00071. eCollection 2016.

3.
4.

Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients.

Wijsman R, Grootjans W, Troost EG, van der Heijden EH, Visser EP, de Geus-Oei LF, Bussink J.

Nucl Med Commun. 2016 Jan;37(1):66-73. doi: 10.1097/MNM.0000000000000409.

PMID:
26440570
5.

The mechanical microenvironment in cancer: How physics affects tumours.

Nagelkerke A, Bussink J, Rowan AE, Span PN.

Semin Cancer Biol. 2015 Dec;35:62-70. doi: 10.1016/j.semcancer.2015.09.001. Epub 2015 Sep 5. Review.

PMID:
26343578
6.

Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy.

Wijsman R, Dankers F, Troost EG, Hoffmann AL, van der Heijden EH, de Geus-Oei LF, Bussink J.

Radiother Oncol. 2015 Oct;117(1):49-54. doi: 10.1016/j.radonc.2015.08.010. Epub 2015 Sep 2.

PMID:
26341608
7.

Machine Learning methods for Quantitative Radiomic Biomarkers.

Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJ.

Sci Rep. 2015 Aug 17;5:13087. doi: 10.1038/srep13087.

8.

Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer.

Parmar C, Leijenaar RT, Grossmann P, Rios Velazquez E, Bussink J, Rietveld D, Rietbergen MM, Haibe-Kains B, Lambin P, Aerts HJ.

Sci Rep. 2015 Jun 5;5:11044. doi: 10.1038/srep11044.

9.

Epidermal growth factor receptor imaging in human head and neck cancer xenografts.

van Dijk LK, Boerman OC, Kaanders JH, Bussink J.

Acta Oncol. 2015;54(9):1263-7. doi: 10.3109/0284186X.2015.1063778. Epub 2015 Aug 6.

PMID:
26248024
10.

PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.

van Dijk LK, Yim CB, Franssen GM, Kaanders JH, Rajander J, Solin O, Grönroos TJ, Boerman OC, Bussink J.

Contrast Media Mol Imaging. 2016 Jan;11(1):65-70. doi: 10.1002/cmmi.1659. Epub 2015 Aug 4.

PMID:
26242487
11.

GABARAPL1 is required for increased EGFR membrane expression during hypoxia.

Keulers TG, Schaaf MB, Peeters HJ, Savelkouls KG, Vooijs MA, Bussink J, Jutten B, Rouschop KM.

Radiother Oncol. 2015 Sep;116(3):417-22. doi: 10.1016/j.radonc.2015.06.023. Epub 2015 Jul 8.

PMID:
26164772
12.

Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer.

Usmanij EA, de Geus-Oei LF, Bussink J, Oyen WJ.

Curr Opin Pulm Med. 2015 Jul;21(4):314-21. doi: 10.1097/MCP.0000000000000182. Review.

PMID:
25978629
13.

PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.

van Dijk LK, Boerman OC, Kaanders JH, Bussink J.

Clin Cancer Res. 2015 Aug 15;21(16):3602-9. doi: 10.1158/1078-0432.CCR-15-0348. Epub 2015 Apr 30. Review.

PMID:
25931452
14.

PET in the management of locally advanced and metastatic NSCLC.

Grootjans W, de Geus-Oei LF, Troost EG, Visser EP, Oyen WJ, Bussink J.

Nat Rev Clin Oncol. 2015 Jul;12(7):395-407. doi: 10.1038/nrclinonc.2015.75. Epub 2015 Apr 28. Review.

PMID:
25917254
15.

Poor prognosis of constitutive γ-H2AX expressing triple-negative breast cancers is associated with telomere length.

Nagelkerke A, van Kuijk SJ, Martens JW, Sweep FC, Hoogerbrugge N, Bussink J, Span PN.

Biomark Med. 2015;9(4):383-90. doi: 10.2217/bmm.15.2.

PMID:
25808442
16.

γ-H2AX foci in peripheral blood lymphocytes to quantify radiation-induced DNA damage after 177Lu-DOTA-octreotate peptide receptor radionuclide therapy.

Bussink J, Span PN.

J Nucl Med. 2015 Apr;56(4):501-2. doi: 10.2967/jnumed.115.153841. Epub 2015 Feb 26. No abstract available.

17.

Biology of hypoxia.

Span PN, Bussink J.

Semin Nucl Med. 2015 Mar;45(2):101-9. doi: 10.1053/j.semnuclmed.2014.10.002. Review.

PMID:
25704383
18.

111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.

van Dijk LK, Boerman OC, Franssen GM, Kaanders JH, Bussink J.

J Nucl Med. 2015 Feb;56(2):287-92. doi: 10.2967/jnumed.114.148296. Epub 2014 Dec 31.

19.

In response to "histopathologic validation of 3'-deoxy-3'-(18)F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice".

Troost EG, Hoeben BA, Laverman P, Bussink J, Oyen WJ.

Radiother Oncol. 2015 Mar;114(3):417-8. doi: 10.1016/j.radonc.2014.11.040. Epub 2014 Dec 12. No abstract available.

PMID:
25511411
20.

In-treatment assessment of response in locally advanced NSCLC: paving the way for personalized medicine.

Usmanij EA, Bussink J, de Geus-Oei LF.

Lung Cancer. 2014 Dec;86(3):374. doi: 10.1016/j.lungcan.2014.10.006. Epub 2014 Oct 17. No abstract available.

PMID:
25454200
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk